Potential of Genetic Testing Beyond BRCA1/2 in Ovarian Cancer

Partner | Cancer Centers | <b>The Ohio State University</b>

Leigha Senter, MS, LGC, discusses the implications of identifying genes beyond BRCA1/2 in women with ovarian cancer.

Leigha Senter, MS, LGC, associate professor, Division of Human Genetics, Department of Internal Medicine, The Ohio State University Wexner Medical Center, discusses the implications of identifying genes beyond BRCA1/2 in women with ovarian cancer.

There are a number of other gene alterations that carry an increased risk of developing cancer, says Senter. These mutations can help shed light on the origin of the cancer, and can indicate whether further testing for other cancers should be considered. Also, they can guide screening and treatment interventions for family members who may be at risk.

Further investigation with these mutations may lead to additional targeted therapies, concludes Senter.